These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3481140)

  • 41. One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application.
    Ponjee GA; Vader HL; de Wild PJ; Janssen GW; van der Graaf F
    Clin Chem; 1991 Jul; 37(7):1235-44. PubMed ID: 1855296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Automated spectrophotometric heparin assays. Comparison of methods.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):195-204. PubMed ID: 6735277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Control of the therapeutic heparin dosage in platelet rich citrate plasma after protamine neutralization].
    Görss EW; Maercker W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):815-22. PubMed ID: 2436996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers.
    Kroon C; ten Hove WR; de Boer A; Kroon JM; van der Pol JM; Harthoorn-Lasthuizen EJ; Schoemaker HC; van der Meer FJ; Cohen AF
    Circulation; 1992 Nov; 86(5):1370-5. PubMed ID: 1423948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring heparin therapy--a role for the chromogenic assay.
    Chong LL; Sussman II; Spaet TH
    Clin Lab Haematol; 1983; 5(1):61-5. PubMed ID: 6851437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The safe use of epidural anesthesia after subcutaneous injection of low-dose heparin in general abdominal surgery.
    Kassis J; Fugère F; Dubé S
    Can J Surg; 2000 Aug; 43(4):289-94. PubMed ID: 10948690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HEPTEST: a suitable method for monitoring heparin during pregnancy.
    Campbell PJ; Tirvengadum MA; Pickering W; Cohen H; Ryan KE
    Clin Lab Haematol; 1999 Jun; 21(3):193-9. PubMed ID: 10448601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Standard assays underestimate the concentration of heparin in neonatal plasma.
    Schmidt B; Mitchell L; Ofosu F; Andrew M
    J Lab Clin Med; 1988 Nov; 112(5):641-3. PubMed ID: 3183496
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measurement of heparin in plasma: influence of inter-subject and circadian variability in heparin sensitivity according to method.
    Scully MF; Decousus HA; Ellis V; Parker C; Girard P; Kakkar VV
    Thromb Res; 1987 May; 46(3):447-55. PubMed ID: 3603435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of platelet factor 4 (PF4) on assays of plasma heparin.
    Levine SP; Sorenson RR; Harris MA; Knieriem LK
    Br J Haematol; 1984 Aug; 57(4):585-96. PubMed ID: 6743573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Study on a new chromogenic substrate for the prothrombin time determination.
    Girolami A; Santarossa A; Martinelli S; Sartori MT; Visentin I
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(6):881-95. PubMed ID: 2453419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparison of heparin-induced prolongation of APTT in 12 different laboratories in Kyushu area].
    Tanaka N; Manabe M; Yamashita S; Ikeda K; Obayashi K; Uchiba M; Ando Y
    Rinsho Byori; 2013 Jul; 61(7):576-82. PubMed ID: 24205697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thioester chromogenic substrates for human factor VIIa: substituted isocoumarins are inhibitors of factor VIIa and in vitro anticoagulants.
    Kam CM; Vlasuk GP; Smith DE; Arcuri KE; Powers JC
    Thromb Haemost; 1990 Aug; 64(1):133-7. PubMed ID: 2274918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing methods of establishing the aPTT therapeutic range of heparin.
    Liepman CI; Koerber JM; Mattson JC; Westley SJ; Smythe MA
    Ann Pharmacother; 2003 Jun; 37(6):794-8. PubMed ID: 12773063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assay of heparin in plasma using a chromogenic substrate and its clinical applications.
    Hasegawa H; Oguma Y; Takei H; Seya T; Yamauchi M; Murakoshi T; Nagata H; Murao M
    Jpn Heart J; 1980 May; 21(3):367-80. PubMed ID: 7401317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions in heparin therapy.
    Werner M; Gallagher JV; Ballo MS; Karcher DS
    Am J Clin Pathol; 1994 Aug; 102(2):237-41. PubMed ID: 8042595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients.
    Rosborough TK
    Am J Clin Pathol; 1997 Dec; 108(6):662-8. PubMed ID: 9384448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring heparin and haemostasis during reconstruction of the abdominal aorta.
    Porte RJ; de Jong E; Knot EA; de Maat MP; Terpstra OT; van Urk H; Groenland TH
    Eur J Vasc Surg; 1987 Dec; 1(6):397-402. PubMed ID: 3503034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A proposed model to monitor heparin therapy using the concentrated thrombin time which allows standardisation of reagents and improved estimation of heparin concentrations.
    Ray MJ; Perrin EJ; Smith IR; Hawson GA
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):515-21. PubMed ID: 8874861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A clinical evaluation of automated chromogenic tests as substitutes for conventional prothrombin time and activated partial thromboplastin time tests.
    Duncan A; Bowie EJ; Owen CA; Fass DN
    Clin Chem; 1985 Jun; 31(6):853-5. PubMed ID: 3995763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.